Mustafa Akbiek, M.D
NPI 1679989115 · Pulmonary Disease Physician · Naples, FL
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1679989115
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D
- Sex
- Male
- Sole proprietor
- Yes
- License
- ME132036 (FL)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
11 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
3,004 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 671 | $129 |
| Subsequent Hospital Care With Moderate Levelof Medical Decision Making, If Using Time, at Least 50 Minutes99233 | 546 | $119 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 294 | $55 |
| Test to Determine Lung Volumes Using Sensors94726 | 293 | $55 |
| Critical Care, First 30-74 Minutes99291 | 277 | $216 |
| Test to Measure Rate of Airflow94375 | 195 | $38 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 342 | 70 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 165 | 87 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 164 | 42 |
| Prednisone | 121 | 91 |
| Budesonide/Glycopyr/Formoterolbrand: Breztri Aerosphere | 75 | 16 |
| Budesonide/Formoterol Fumaratebrand: Symbicort | 75 | 30 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$2,269 across 8 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2014-07-04
- Last updated
- 2021-01-21
- Certified
- 2021-01-21
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.